ZURA
Zura Bio Ltd - Ordinary Shares - Class A

955
Loading...
Loading...
News
all
press releases
Novartis Drug Shows Improvement In Sjögren's Disease In Late-Stage Trials: Analyst Deems Data Positive For Zura Bio As Well
Novartis now sees the potential for the drug to become the first and only targeted treatment approved for patients with the disease.
Stocktwits·29d ago
News Placeholder
More News
News Placeholder
Zura Bio to Present at the Leerink Partners Global Healthcare Conference
Zura Bio Limited (Nasdaq: ZURA) (Zura Bio), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that...
Business Wire·7mo ago
News Placeholder
Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis
Zura Bio Limited (Nasdaq: ZURA) (Zura Bio), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced the...
Business Wire·9mo ago
News Placeholder
Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference
Zura Bio Limited (Nasdaq: ZURA) (Zura Bio), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that...
Business Wire·10mo ago
News Placeholder
Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis
Zura Bio Limited (Nasdaq: ZURA) (Zura Bio), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced the...
Business Wire·10mo ago
News Placeholder
Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
Zura Bio Limited (Nasdaq: ZURA) (Zura Bio), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported...
Business Wire·10mo ago
News Placeholder
Zura Bio to Present at Three Upcoming Investor Conferences in September
Zura Bio Limited (Nasdaq: ZURA) (Zura Bio), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that...
Business Wire·1y ago
News Placeholder
Zura Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Zura Bio Limited (Nasdaq: ZURA) (Zura Bio), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported its...
Business Wire·1y ago
News Placeholder
Zura Bio Completes Exchange Offer and Consent Solicitation and Notice to Exercise Right to Exchange Remaining Outstanding Warrants
Zura Bio Limited (Nasdaq: ZURA) (Zura Bio or the Company), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that...
Business Wire·1y ago
News Placeholder
Zura Bio Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to its Warrants
Zura Bio Limited (Nasdaq: ZURA) (Zura Bio or the Company), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced the...
Business Wire·1y ago

Latest ZURA News

View

Advertisement. Remove ads.

Advertisement. Remove ads.